April 5, 2012
/PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) today announced that the Company will host a special event entitled "
Treatment of Opioid Dependence: The Future Role of BEMA Buprenorphine/Naloxone"
for investors and analysts on
Wednesday, April 11, 2012
in New York City. This event will include
insightful discussion from medical experts with extensive experience in the management of opioid dependence and treatment with buprenorphine.
In addition to presentations by independent experts in the management of opioid dependence, BDSI's management will speak about the clinical progress of BEMA Buprenorphine/Naloxone (BNX) for the potential treatment of opioid dependence.
The expert presentations at this event will include:
- "Understanding Opioid Dependence" by Gregory Sullivan, M.D. – Board certified in Addiction Medicine and Medical Director of Parkway Medical Center in Birmingham, Alabama. For twenty years, Dr. Sullivan has been actively involved in government and pharmaceutical research on the mechanism, biology and treatment of addiction and pain.
- "Buprenorphine in the Successful Management of Opioid Dependence" by Aafaque Akhter, M.D. – Former instructor of Psychiatry at Harvard Medical School and Board certified in Psychiatry and Neurology. Dr. Akhter is the founder and CEO of New England Counseling & Treatment Center, and Norton Health Care, which is one of the few clinics in the country exclusively focused on opiate addiction.
BDSI plans on initiating a pivotal pharmacokinetic study and the safety study for BNX in the third quarter of 2012. Results of the pivotal pharmacokinetic study are anticipated to be available late in the third quarter of this year. If positive, this would allow for an anticipated New Drug Application (NDA) filing in the first half of 2013.